<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634266</url>
  </required_header>
  <id_info>
    <org_study_id>TRICI-HF</org_study_id>
    <nct_id>NCT04634266</nct_id>
  </id_info>
  <brief_title>TRICuspid Intervention in Heart Failure Trial</brief_title>
  <acronym>TRICI-HF</acronym>
  <official_title>TRICuspid Intervention in Heart Failure Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LMU Klinikum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Diabetes Center North Rhine-Westphalia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LMU Klinikum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional tricuspid regurgitation (TR) is a serious and progressive disease. Guidelines&#xD;
      recommend surgical valve repair of severe TR in symptomatic patients. Despite its association&#xD;
      with excess mortality and morbidity, TR has been relatively neglected and is severely&#xD;
      undertreated. In particular this is because isolated tricuspid surgery remains associated&#xD;
      with high mortality rates, and thus, patients with severe TR are often deemed inoperable due&#xD;
      to severe co-morbidities and frailty. In recent years, percutaneous CE-mark approved&#xD;
      techniques for transcatheter tricuspid valve treatment (TTVT) have emerged as alternatives to&#xD;
      surgery. These include (I) transcatheter annuloplasty devices (Tricuspid Cardioband) and (II)&#xD;
      transcatheter edge-to-edge repair (TriClip, PASCAL). Several non-randomized studies suggested&#xD;
      improved functional outcomes after TTVT, however, to data there is no evidence from&#xD;
      randomized controlled trials addressing the actual efficacy of TTVT. The TRICuspid&#xD;
      Intervention in Heart Failure trial (TRICI-HF trial) will assess the concept that TTVT will&#xD;
      translate into a reduced morbidity and mortality. Patients will be randomly assigned in a 2:1&#xD;
      fashion to TTVT plus OMT (Experimental group) or OMT alone (Control group). TRICI-HF is an&#xD;
      industry-independent, investigator-initiated strategy study and investigators may choose any&#xD;
      suitable CE-marked percutaneous system &quot;on-label&quot; for TTVT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective, controlled, multicenter, randomized, open label trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality or heart failure hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of time to all-cause mortality or heart failure hospitalization - whichever occurs first - at a minimum follow-up of 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality (unadjusted and adjusted for TR severity at baseline)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure hospitalizations (frequency and length; unadjusted and adjusted for TR severity at baseline)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life as assessed by the MLHFQ from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention rates for recurrent tricuspid regurgitation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA Class from baseline (≥III/IV to ≤I/II)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk test distance from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiographic parameters (among others: TR grade I-V, RV dimension and function, LV dimension and function, estimation of sPAP)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of tricuspid stenosis (mean inflow gradient &gt;5mmHg)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripheral edema assessed by the edema scale (grade I-IV) and subject weight (kilograms) from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of diuretic drugs and heart failure medications from baseline (type and dosage)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory markers for cardiac, renal and hepatic function (complete blood count, NT-proBNP, eGFR, serum creatinine, bilirubin, AST, ALT and gGT)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of transcatheter tricuspid valve intervention</measure>
    <time_frame>1 month</time_frame>
    <description>Major adverse events that are related to the intervention and are relevant for patients undergoing TTVT: Mortality, life threatening bleeding (defined as BARC bleeding type 3 and 5), major vascular or cardiac structural complications requiring intervention, or mechanical circulatory support.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Heart Failure Attributable to Severe Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Experimental intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter tricuspid valve treatment (TTVT) plus optimal medical therapy (OMT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>OMT for severe tricuspid regurgitation in right-sided heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter tricuspid valve treatment (TTVT)</intervention_name>
    <description>Percutaneous CE-mark approved techniques for transcatheter tricuspid valve treatment (TTVT): These include (I) transcatheter annuloplasty devices (Tricuspid Cardioband) and (II) transcatheter edge-to-edge repair (TriClip, PASCAL).</description>
    <arm_group_label>Experimental intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The following inclusion criteria were defined to assure generalizability of the population&#xD;
        to be studied:&#xD;
&#xD;
          -  Subject is symptomatic due to severe TR despite being on stable OMT for at least 30&#xD;
             days based on judgment of the local heart team. Patients with reduced left ventricular&#xD;
             ejection fraction (HFrEF) will likely constitute a minority among eligible patients&#xD;
             with isolated severe tricuspid regurgitation (9,13). However, HFrEF patients enrolled&#xD;
             into the trial need to be on stable guideline-directed medical therapy for at least 4&#xD;
             weeks..&#xD;
&#xD;
          -  Subject is at intermediate or greater estimated risk of mortality with tricuspid valve&#xD;
             surgery based on judgment of the local heart team&#xD;
&#xD;
          -  New York Heart Association (NYHA) Functional Class II, III or IVa&#xD;
&#xD;
          -  Femoral vein access and valve anatomy are determined to be feasible for interventional&#xD;
             treatment (including sufficient quality of TTE and TEE imaging)&#xD;
&#xD;
          -  Age ≥ 18 years at time of consent&#xD;
&#xD;
          -  Subject must provide written informed consent prior to any trial related procedure&#xD;
&#xD;
        The following exclusion criteria were selected to define a representative study cohort:&#xD;
&#xD;
          -  Presence of severe aortic, mitral or pulmonary valve disease OR&#xD;
             surgical/interventional treatment at the aortic, mitral or pulmonary valves prior 60&#xD;
             days&#xD;
&#xD;
          -  Right heart catheterization (mandatory) with systolic pulmonary artery pressure &gt; 70&#xD;
             mmHg or substantial pre-capillary pulmonary hypertension (defined as mean pulmonary&#xD;
             artery pressure (mPAP) &gt;30 mmHg plus transpulmonary gradient (TPG) &gt;17 mmHg or&#xD;
             pulmonary vascular resistance (PVR) &gt;5 wood units)&#xD;
&#xD;
          -  Tricuspid valve stenosis (tricuspid mean gradient &gt; 5 mmHg)&#xD;
&#xD;
          -  Pacemaker or ICD leads that would prevent appropriate TTVT&#xD;
&#xD;
          -  Prior tricuspid valve procedures or tricuspid valve leaflet anatomy that would&#xD;
             interfere with appropriate TTVT (e.g. calcification, Ebstein anomaly, coaptation&#xD;
             defect &gt; 8mm for planned leaflet- and annuloplasty-based therapy)&#xD;
&#xD;
          -  Chronic renal failure requiring dialysis&#xD;
&#xD;
          -  Tricuspid valve anatomy not evaluable by TTE and TEE&#xD;
&#xD;
          -  Myocardial infarction or cerebrovascular accident within prior 90 days&#xD;
&#xD;
          -  Life expectancy of less than 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joerg Hausleiter, MD</last_name>
    <phone>+4989440072361</phone>
    <email>joerg.hausleiter@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Stocker, MD</last_name>
    <phone>+49894400712625</phone>
    <email>thomas.stocker@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Comberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum Nordrhein-Westfalen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Volker Rudolph</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schüchtermann-Klinik</name>
      <address>
        <city>Bad Rothenfelde</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Marek Kowalski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ulf Landmesser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Volkmar Falk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Georg Nickenig</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital Dortmund</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Helge Möllmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexander Lauten</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tienush Rassaf</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas Zeiher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Bode</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Holger Nef</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Claudius Jacobshagen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum UKE</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Prof. Mathey/Schofer</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Joachim Schofer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Schulze</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Derk Frank</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephan Baldus</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Philipp Lurz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephan von Bardeleben</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Joerg Hausleiter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joerg Hausleiter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Stocker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Braun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steffen Massberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Siegburg</name>
      <address>
        <city>Siegburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Boekstegers</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LMU Klinikum</investigator_affiliation>
    <investigator_full_name>Thomas Stocker</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

